Trial Profile
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms OptiPOM
- 07 Jun 2021 Status changed from active, no longer recruiting to discontinued due to feasibility (low patient accrual and financial reasons).
- 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 27 Apr 2020 Status changed from active, no longer recruiting to recruiting.